Playback speed
10 seconds
CLL State of the Art Update: Ibrutinib Prolongs PFS Compared to CIT, Combinations Achieve uMRD, Venetoclax Obinutuzumab is Highly Effective, & Next Generation BTKi's Are Better Tolerated
316 views
October 18, 2019
Login to view comments.
Click here to Login